FDA Seeks Comparative Trials, Public Relations Makeover For Obesity Drugs
Executive Summary
FDA's research priorities for anti-obesity medicines include gathering data on long-term use of phentermine, particularly in comparison to newer agents, Metabolic & Endocrine Drug Products Division Director David Orloff, MD, told the FDA Science Board Advisory Committee April 22
You may also be interested in...
Obesity Drug Trials Should Be Shorter, Have Broader Endpoints, PhRMA Says
The Pharmaceutical Research & Manufacturers of America is asking FDA to change its guidance on the development of weight loss drugs to allow shorter trials
Obesity Drug Trials Should Be Shorter, Have Broader Endpoints, PhRMA Says
The Pharmaceutical Research & Manufacturers of America is asking FDA to change its guidance on the development of weight loss drugs to allow shorter trials
FDA Will Publish “Critical Path” Opportunities List By Fall, Woodcock Says
FDA plans to finalize its list of "Critical Path" opportunities by early fall, Acting Deputy Commissioner for Operations Janet Woodcock said